Literature DB >> 16763862

[Intravitreal bevacizumab for neovascular age-related macular degeneration].

M S Ladewig1, F Ziemssen, G Jaissle, H-M Helb, H P N Scholl, N Eter, K U Bartz-Schmidt, F G Holz.   

Abstract

The efficacy and safety of the therapeutic anti-VEGF concept has already been demonstrated for pegaptanib and ranibizumab. Bevacizumab acts as an antibody against all VEGF-A isoforms and has been developed for oncological indications with intravenous application. Initial reports on intravitreal administration in patients with neovascular age-related macular disease (AMD) have shown beneficial morphological and functional effects. In the meantime, bevacizumab has been used off-label in thousands of patients with AMD. However, data from prospective, controlled, randomized trials on both safety and efficacy are lacking. Herein recent experiences with bevacizumab are summarized and discussed. Furthermore, a web-based platform for online data registration and pooled analyses is presented.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16763862     DOI： 10.1007/s00347-006-1352-5

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  17 in total

Review 1.  Pathogenesis of lesions in late age-related macular disease.

Authors:  Frank G Holz; Daniel Pauleikhoff; Ronald Klein; Alan C Bird
Journal:  Am J Ophthalmol       Date:  2004-03       Impact factor: 5.258

Review 2.  The role of vascular endothelial growth factor in ocular health and disease.

Authors:  Anthony P Adamis; David T Shima
Journal:  Retina       Date:  2005 Feb-Mar       Impact factor: 4.256

3.  [Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  2005-05       Impact factor: 0.700

Review 4.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 5.  [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].

Authors:  S Michels; P J Rosenfeld
Journal:  Klin Monbl Augenheilkd       Date:  2005-06       Impact factor: 0.700

6.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.

Authors:  J Mordenti; R A Cuthbertson; N Ferrara; K Thomsen; L Berleau; V Licko; P C Allen; C R Valverde; Y G Meng; D T Fei; K M Fourre; A M Ryan
Journal:  Toxicol Pathol       Date:  1999 Sep-Oct       Impact factor: 1.902

8.  Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Authors:  Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2002-03

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.

Authors:  A P Adamis; D T Shima; M J Tolentino; E S Gragoudas; N Ferrara; J Folkman; P A D'Amore; J W Miller
Journal:  Arch Ophthalmol       Date:  1996-01
View more
  20 in total

1.  Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Ratimir Lazic; Nikica Gabric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  [Intravitreal bevacizumab for recurring choroidal neovascularisation].

Authors:  M Niemeyer; L Hefner; C Jochmann; P Wiedemann
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

3.  [Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks].

Authors:  A Lommatzsch; G Spital; M Trieschmann; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

Review 4.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

5.  A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.

Authors:  Dae Hyun Park; Hae Jung Sun; Sung Jin Lee
Journal:  Int Ophthalmol       Date:  2016-11-08       Impact factor: 2.031

6.  [Combined intravitreal injection of bevacizumab and SF6 gas for treatment of submacular hemorrhage secondary to age-related macular degeneration].

Authors:  F Höhn; A Mirshahi; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

7.  [Retinochoroidopathy after intravitreal anti-VEGF treatment].

Authors:  M Maier; N Feucht; I Lanzl; P Kook; C P Lohmann
Journal:  Ophthalmologe       Date:  2009-08       Impact factor: 1.059

8.  [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD].

Authors:  K B Schaal; C Engler; F Schütt; A Scheuerle; S Dithmar
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

9.  [Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application].

Authors:  C H Meyer; S Mennel; N Eter
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

Review 10.  A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

Authors:  Jan S A G Schouten; Ellen C La Heij; Carroll A B Webers; Igor J Lundqvist; Fred Hendrikse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-09       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.